Alden Global Capital’s Exact Sciences EXAS Stock Holding History

Alden Global Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-173,500	Closed	-$1.6M	–	27
2015 Q4	$1.6M	Buy	+173,500	New	+$1.61M	0.81%	19

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ZCI

Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Alden Global Capital's EXAS Position: Q1 2016 in Review

Alden Global Capital sold out of Exact Sciences (EXAS) in Q1 2016, closing a stake of 173,500 shares — an estimated $1.6M sold.

Alden Global Capital first reported a position in EXAS in Q4 2015 and held it in 1 quarter. The position peaked at $1.6M in Q4 2015. 167 funds tracked by Wall St. Rank hold EXAS as of Q1 2016.

Alden Global Capital reported no remaining Exact Sciences position as of Q1 2016 after selling out during the quarter.
Alden Global Capital sold 173,500 Exact Sciences shares in Q1 2016, an estimated $1.6M.
Alden Global Capital first reported a position in Exact Sciences in Q4 2015 and held it in 1 quarter.
Alden Global Capital's Exact Sciences position peaked at $1.6M in Q4 2015.
167 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2016.

Based on Alden Global Capital's 13F filing for Q1 2016, filed 13 May 2016.